Compare Tyson Foods, Inc. (TSN) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tyson Foods, Inc. vs Vertex Pharmaceuticals Incorporated — how do they compare? Tyson Foods, Inc. trades at $52.67 (market cap $18.41B), while Vertex Pharmaceuticals Incorporated trades at $508.42 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 6.9× Tyson Foods, Inc.'s market cap, and Tyson Foods, Inc. pays a 3.9% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Tyson Foods, Inc. for 76 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| TSN | VRTX | |
|---|---|---|
Market Cap | $18.41B | $127.55B |
Volume | 3,757,599 | 1,487,944 |
Sector | Consumer Staples | Health |
52-Week High | $68.75 | $557.96 |
52-Week Low | $50.47 | $407.37 |
Typical Hold Time | 76 Days | 120 Days |
Enterprise Value | $25.68B | $121.68B |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Tyson Foods (TSN) trades at $51.70, down 0.52% with mixed technical signals showing neutral overall but bearish moving averages. The company reported Q2 2026 EPS of $0.99, beating expectations, while Q4 2025 missed. Revenue grew to $54.44B in 2025 with thin 1.03% net margins. Analyst consensus is bullish with 53% buy ratings and $65.40 price target, though recent news highlights challenges in the beef segment and ongoing securities investigations.
The stock presents a value opportunity with low P/S (0.33) and reasonable EV/EBITDA (9.83), but faces significant execution risks from beef segment losses and margin pressure. Upside depends on successful business turnaround and resolution of legal concerns, while current price near 52-week lows offers potential for recovery if fundamentals improve.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong fundamentals with $12B revenue, 35% net margin, and robust cash flow. Recent positive Phase 2b data for kidney drug inaxaplin and cystic fibrosis dominance support growth. Earnings show volatility with Q1 beat but Q2 miss against expectations.
Outlook remains positive with 84% analyst buy ratings and $573.50 consensus target offering 13% upside. Key risks include clinical trial outcomes, competitive pressures, and reliance on cystic fibrosis portfolio. The stock presents growth potential through pipeline expansion but faces sector volatility and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Tyson Foods, Inc.
Tyson Foods is the largest U.S. producer of processed chicken and beef. It's also a large producer of processed pork and protein-based products under the brands Jimmy Dean, Hillshire Farm, Ball Park, Sara Lee, Aidells, State Fair, and Raised & Rooted, to name a few. Tyson sells 81% of its products through various U.S. channels, including retailers (47% in fiscal 2021), food service (32%), and other packaged food and industrial companies (10%). In addition, 11% of the company's revenue comes from exports to Canada, Mexico, Brazil, Europe, China, and Japan.
Read more on TSN →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
